“Spiro-pyrrolizidine-benzyloxy hybrid as synergistic partner to doxorubicin cardio-safe breast cancer chemotherapy”
Compounding RP<sub>1</sub> with doxorubicin effectively enhances anticancer activity while potentially reducing the side effects associated with doxorubicin's quinone-hydroquinone moiety. The optimized formulation (80:20) presents a promising approach for improving breast cancer treatment outcomes.
Authors
- H. Manikandan
- M. Raj Kumar
- U. Rajapandiyan
- K. Sivakumar
Institutions
- Sri Chandrasekharendra Saraswathi Viswa Mahavidyalaya (IN)
- Annamalai University (IN)
Publication Details
- Journal
- Future Medicinal Chemistry
- Published
- 2025-10-11
- DOI
- https://doi.org/10.1080/17568919.2025.2570968
- Citations
- 1
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 1.05